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Deceased donor kidney transplantationSensitization to HLA antigens creates an obstacle for the accessibility and success of kidney transplantation
(KT). Highly sensitized patients have longer waiting times and some may never receive a KT.
Aim: To determine the probability of patients on the deceased donor (DD) waiting list to receive a KT based
on the panel reactive antibody percentage (% PRA) in our center.
Methods: The DD waiting list from our institution was analyzed from 01/05 to 08/12 documenting the clinical
variables from donor and potential recipients (ABO blood group), lymphocyte cross-match [CxM (CDC-AHG)]
results, highest % PRA determination, and time on the waiting list. The patients were classiﬁed into 4 groups
based on the % PRA: 0%, 1–19%, 20–79% and 80–100%. The data was analyzed using odds ratio and logistic re-
gression (signiﬁcant p b 0.05).
Results: 58 DD (F:M 34:24, ABO group O = 35, A = 13, B = 10) and 179 potential recipients were analyzed
(F:M 98:81, ABO group O = 127, A = 33, B = 19, participating 4.2 ± 3.8 times with different donors to re-
ceive KT). The mean PRA for the whole group was 22 ± 32%, median [md] 0 (0–98). A total of 100 patients
received KT (mean waiting time 2.2 ± 1.7 years, 12 days–7 years) and their mean % PRA was 11.6 ± 24, md
0 (0–94) vs. 31.4 ± 37 md 8.5 (0–98) in those who have not received a KT. An association between the % PRA
group and KT (p b 0.003) was observed. The probability of receiving KT with a 0% PRA vs. >0% was higher
(OR 2.12, 1.17–3.84). There was no difference between the 0% vs. 1–19% group (OR 1); differences were ob-
served between 0% vs. 20–79% (OR 2.5, 1.18–5.3) and 0% vs. 80–100% (OR 5, 1.67–14.9). For every percent
increase in the PRA above 20%, the risk of not receiving a KT increased by 5% (1–9, p b 0.01).
Conclusions: The probability of receiving a DD kidney transplant is inversely related to the % PRA although a
higher risk for not receiving a KT becomes evident with a PRA >20%.
© 2013 The Authors. Published by Elsevier B.V. Open access under CC BY-NC-ND license.1. Introduction
Kidney transplantation is the preferred treatment modality for pa-
tients with ESRD because of improved patient survival and quality-of-
life over dialysis [1–4]. Several groups have analyzed transplantation
in highly HLA-sensitized patients recently. The risks for transplanta-
tion can be assessed using currently available standard assays. Today,
the techniques that are used to detect anti-HLA antibody includeransplant Congress in Seattle,
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.V. Open access under CC BY-NC-ND lcytotoxicity (CDC) with/without anti-human globulin, ELISA, and ﬂow
cytommetry (using cells and antigen-coated beads). The development
of newer, more sensitive assays has led to an increased ability to deﬁne
highly sensitized patients and identify donor-speciﬁc antibody [2]. Sev-
eral risk factors have been described regarding sensitization to HLA an-
tigens including blood transfusions, pregnancy and previous organ
transplantation. The degree of sensitization creates an obstacle for the
accessibility and success of kidney transplantation [1].
In patients with high panel-reactive antibodies (% PRA) deﬁned as
having a % PRA >30, transplant rates are dramatically reduced be-
cause of the additional immunologic barrier with increased rejection
risk [2]. In 2003, only 6.5% of all kidney transplants that were
performed in the United States were in patients with PRA >80%, de-
spite representing approximately 14% of the waiting list [5,7]. When
these patients receive a transplant, they experience an increased
number of rejection episodes and have poorer graft survival [6].
According to Marfo et al., 35% of the patients on the waiting list are
sensitized with PRA levels >0%, and 15% are highly sensitized with
PRA levels >80% [1].icense.
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plant list can exceed ﬁve years and due to organ shortage, this scenario
is not changing in the near future. It has been thoroughly described that
highly sensitized patients have longer waiting times and some may
never receive a transplant [1]. In Mexico, roughly 75% of renal trans-
plants are from living donors and approximately 2300 kidney trans-
plants per year have been performed during the last 3 years [8].
Although there has been a decrease in the mortality rate of
patients on dialysis, approximately 15 to 20% still die each year, which
emphasizes the importance of early transplantation [4,9]. There is an
evident ﬁnancial cost and emotional burden secondary to maintaining
a highly sensitized patient on dialysis in comparison to early transplan-
tation. The impact of kidney transplantation on morbidity, mortality,
quality of life and medical expenses is undeniable.
The main objective of this study was to determine the probability of
patients in the deceaseddonor (DD)waiting list at theNational Institute
of Medical Sciences and Nutrition (INCMNSZ) in Mexico City to receive
a kidney transplant (KT), based on the degree of sensitization deter-
mined by % PRA. Acute rejection rate, graft function, patient and graft
survival, and causes for patient death/graft loss were also analyzed.
This protocol was approved by the Institutional Committee of
Medical Ethics and performed in accordance with the revised Decla-
ration of Helsinki content and Good Clinical Practice Guidelines.
2. Patients and methods
The renal transplant DD waiting list database was reviewed from
January 2005 to August 2012 at the Histocompatibility Laboratory at
INCMNSZ. For each DD event, we documented the donor's demo-
graphic characteristics (age and gender), donor's blood group (ABO
group), the number and ABO group of all the potential recipients
considered, the results of the lymphocyte cross-match test [CxM
(AHG-CDC)] for each potential recipient considered, the % PRA of
each potential recipient (highest % PRA documented in the last three
determinations) and which patients consequentially received a DD
kidney transplant.
Anti-HLA antibodies were tested by the Luminex technique using
test kits purchased from One Lambda, Inc., Canoga Park, CA. In the
patients on the waiting list, a LabScreen Mixed Classes I & II and a
LabScreen PRA Classes I & II were simultaneously performed. Only
thosewith positive results in either test received a Labscreen Single An-
tigen test. When available, the result of pre-transplant DSA assessment
using the LABScreen Single Antigen Classes I & II was gathered for the
analysis. Crossmatches were performed just prior to transplantation
with the standard AHG enhanced complement-dependent cytotoxicity
test (AHG-CDC-CXM) for T and B cells. Renal transplants were
performed only when AHG-CDC CXMs were negative.
The potential recipients considered during the DD events were
classiﬁed into 5 groups according to their % PRA: Group 1 (0%),
group 2 (1–19%), group 3 (20–79%), group 4 (80–100%) and group
5 (unknown PRA). The patients in group 5 (unknown) were included
in the deceased donor waiting list in a time period when the % PRA
assay was not part of the regular practice in our setting.
In our institution, kidney allocation to patients on the waiting list
has been based exclusively on a negative T and B cells AHG-CDC
cross-match, the time on waiting list and blood group (equal ABO
group with the donor). Patients without vascular and peritoneal
access for dialysis are considered emergencies and always have had
priority in our setting. All of the patients that undergo a DD KT at
out institution receive some modality of induction therapy, whether
anti-CD25monoclonal antibodies or thymoglobulin, and is mostly de-
ﬁned by the immunological patient risk. During this time period, the
immunosuppression regimen for this group of patients consisted of
tacrolimus, mycophenolate mofetil, and prednisone.
Clinical information regarding 1-year post-KT graft function
and/or the last graft function evaluation was gathered from thecorresponding patient records. Causes of graft loss and patient
death were documented.
The graft biopsy registry was analyzed to obtain the information
regarding the total number of graft dysfunction biopsies performed,
and acute rejection events documented whether cellular, humoral
or both. The histological analysis and diagnosis were performed using
the current BANFF criteria at the time of the graft biopsy [11–17].
Graft dysfunction was deﬁned as SCr increase of ≥25% from baseline
in the absence of an identiﬁed cause.
The statistical analysis was performed using odds ratio with prior
group stratiﬁcation, logistic regression analysis, Kaplan Meier method
and Log Rank. A p value b0.05 was considered statistically signiﬁcant
with a conﬁdence interval of 95%. For categorical variables, an analy-
sis to determine frequencies, proportions, Chi2, and Spearman corre-
lation coefﬁcient was also performed.
3. Results
3.1. Transplant characteristics and organ assignment
Fifty-eight DD events with a female to male ratio of 34:24 and a mean age of
35.4 ± 13.3 were identiﬁed. The ABO group distribution among these donors was of
35 donors for group “O”, 13 donors for group “A” and 10 donors for group “B”. A
group of 179 potential kidney transplant recipients was included in the analysis all of
whom were older than 18 years of age, with a female to male ratio of 98:81 and a
ABO group distribution of 127 patients for group “O”, 33 patients for group “A” and
19 patients for group “B”. The mean PRA for all the potential recipients was 22 ±
32%, median [md] 0 (0–98). Males had a mean % PRA of 11.7 ± 26 md 0 (0–97) vs.
females with a mean % PRA of 30.9 ± 35 md 13.5 (0–98).
Overall, potential kidney transplant recipients participated in a mean of 4.2 ± 3.8
cross-matches with potential donors for kidney allocation. The mean number of pa-
tients included for cross-match testing per donation event was 21 for ABO group “O”,
8 for group “A”, and 5 for group “B”.
A total of 100 patients received a KT with a mean time on the DD waiting list of
2.2 ± 1.7 years (12 days–7 years) vs. 5.2 ± 3.7 years (119 days–18.5 years) in the
patients (n = 79) that remain in the waiting list for the period of time of this analysis.
The mean % PRA of the KT recipients was 11.6 ± 24 md 0 (0–94) vs. 31.4 ± 37 md 8.5
(0–98) in those who have not received a KT. Regarding the administration of induction
therapy, in the period of January 2005 to August 2012, 57% received anti-CD25 mono-
clonal antibodies (Daclizumab or Simulect) and 43% thymoglobulin. None of these pa-
tients were involved in any sort of desensitization protocol prior to KT.
3.2. Risk assessment
A statistically signiﬁcant association between a lower % PRA group and receiving a
KT was observed (p b 0.003). A Kaplan Meier curve depicting the percentage of pa-
tients without a KT among the different % PRA groups adjusted for time on the waiting
list (years) is presented in Fig. 1. The probability of receiving KT with a 0% PRA vs. >0%
was higher (OR 2.12, 1.17–3.84). There was no difference in the probability of receiving
a KT between the 0% vs. 1-–19% group (OR 1). In the probability analysis of the group
with 0% vs. 20–79% and 0% vs. 80–100% the odds ratio was 2.5 (1.18–5.3) and 5 (1.67–
14.9), respectively. For every percent increase in the PRA above 20%, the risk of not re-
ceiving a KT increased by 5% (1–9, p b 0.01). The probability analysis is presented in
Table 1. This analysis was performed on a population level and not by calculating indi-
vidual patient probabilities using HLA typing and HLA speciﬁc antibodies towards pos-
sible organ donors.
There was no association observed between the recipient's ABO group and receiv-
ing a KT (p .126). A Spearman correlation coefﬁcient of .135 was determined between
the % PRA and the number of times potential recipients were considered for DD renal
transplantation.
In Fig. 2, the proportion of DD renal transplants performed at the INCMNSZ based
on the % PRA for the period analyzed is presented. As observed, the number of patients
receiving a KT in this period of time for group 1 (PRA0%) conformed the 50% of the KT
procedures performed.
3.3. Graft biopsies and acute rejection rates
In this group of KT recipients, a mean number of 2.1 ± 1.6 graft biopsies (protocol
ﬁrst year biopsies and graft dysfunction biopsies) were performed in their follow-up
period by the time of this study. The mean number of biopsies performed for indication
(dysfunction) was 1.13 ± 1.26. Overall, acute rejection (cellular, humoral, or both)
was diagnosed in 20%. Further analysis of the acute rejection rates by % PRA group is
presented in Table 2 and the distribution of acute cellular rejection and acute humoral
rejection by % PRA group is presented in Fig. 3.
In a successive outcome analysis regarding the presence of pre-transplant donor
speciﬁc antibodies (DSA, mean ﬂuorescence index >500), 76% (38/50) of renal trans-
plant recipients were evaluated and 13% (n = 5) had positive pre-transplant DSA (PRA
Fig. 1. Kaplan Meier curve depicting the percentage of patients without a KT among the
different % PRA groups adjusted for time on the waiting list (years).
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Fig. 2. Proportion of patients receiving a KT in each % PRA group from 2005 to 2012.
156 I.C. Bostock et al. / Transplant Immunology 28 (2013) 154–15820–79% n = 3, 1–19% n = 1, and unknown n = 1). A statistically signiﬁcant associa-
tion between the % PRA and the presence of pre-transplant DSA was observed (p
.025). Of those patients with pre-transplant DSA, histological evidence of humoral re-
jection was observed in 60% of cases.
3.4. Graft function
Overall, at a mean follow up posttransplant period of 3.3 ± 2.2 years 95 of the 100
KT recipients included in this study continued to have a functioning graft (estimated
glomerular ﬁltration rate, eGFR >15 ml/min). The latest mean serum creatinine
(SCr) for the whole group is 1.5 ± 1.2 mg/dl, and the corresponding eGFR by MDRD
at year 1 post-KT, and in their most current determination was 62.1 ± 19.6 ml/min
and 60.3 ± 22 ml/min, respectively. The graft function analysis by % PRA groups is
presented in Table 2. In the patients that had an episode of acute rejection, the latest
mean eGFR was 43 ± 22.9 ml/min vs. 67.7 ± 17.9 ml/min in those patients that
never have had an episode of acute rejection. One patient included in this patient pop-
ulation endured acute graft loss secondary to primary graft nonfunction, hyperacute
rejection with necrotizing arteritis, 0% PRA, negative anti-HLA and negative
anti-MICA antibodies [10]. This patient was subsequently transplanted in a second oc-
casion with an adequate outcome and current functioning graft. Five additional pa-
tients had lost their graft at the time of this analysis, with a mean time to return to
dialysis of 2.3 ± 2 years and a distribution among the % PRA groups of 3 patients in
group 5 (unknown), 1 in group 2 (1–19 %PRA) and 1 in group 3 (20–79% PRA). The
cause of graft loss in these patients, determined by tissue biopsy was interstitial
ﬁbrosis/tubular atrophy (n = 4) and chronic cellular rejection (n = 1). One patient
with graft loss died during this time period, having return to hemodialysis prior to
the event.
4. Discussion
Even though the probability of receiving a KT from a DD is inverse-
ly related to the % PRA, during the time period analyzed in this study
we observed that in the past 7 years there has been a number of high-
ly sensitized patients that receive a DD renal transplant (~10% with %
PRA >80). The risk of not receiving a KT based on the % PRA in this
analysis, only became evident with a PRA >20%. For every percent in-
crease in the PRA above 20%, the risk of not receiving a KT increased
by 5% (1–9, p b 0.01).
It is important to mention that although the % PRA is not entirely
speciﬁc in regard to alloreactivity towards the donor, it does provide
an indirect measure to estimate the probability of the presence of DSA
and/or a positive crossmatch [1,2]. Furthermore, this is supported by
the distribution of organ assignment among % PRA groups 1 and 2 inTable 1
Probability of receiving a KT among the different % PRA groups.
%PRA Probability of KT (OR)
0% vs. >0% 2.12 (1.17–3.84)
0% vs. 1–19% 1
0% vs. 20–79% 2.5 (1.18–5.3)
0% vs. 80–100% 5 (1.67–14.9)contrast with groups 3 and 4 (Fig. 3) in which it becomes clear that
the patients with lower % PRA are receiving a kidney more often
than those with higher percentages.
Pre-transplant HLA highly sensitized patients portend a higher
risk for acute rejection after transplantation. Interestingly, in this se-
ries the documented rate of acute rejection – whether cellular or hu-
moral – across the groups 1 to 4 was similar. It is important to
mention however, that the low number of patients who received a
kidney transplant in groups 2 to 4 preclude to have statistical power
to detect signiﬁcant differences compared to unsensitized patients
(group 1 = PRA 0%).
The humoral rejection rates were similar throughout the % PRA
groups as well as in group 1 (0%), which implies that the rejection
rate is not entirely dependent on the % PRA. In this scenario, risk factors
for the occurrence of humoral rejection episodes could be linked to
inadequate immunosuppression adherence and/or drug minimization,
as recently demonstrated [18], however we did not search for patient's
compliance to immunosuppressive therapy in this analysis, therefore the
cause of the 8% acute humoral rejection episodes (alone or combined
with cellular rejection) in the 0% PRA group remains elusive.
Overall, the current acute rejection rate reported by the OPTN/SRTR
in DD KT is 11.6% in the ﬁrst year post-KT with a tendency to increase
thereafter to attain ~19% at 60 months post-KT [9]; our series showed
similar numbers with an overall acute rejection rate of 20% at a mean
follow up post-transplant period of 3.3 ± 2.2 years. It is worth men-
tioning that the 35% acute rejection episodes in the unknown
pre-transplant PRA group suggest that a number of patients included
in this group were highly sensitized. Regarding the pre-transplant sen-
sitization status, it is important to mention that in those patients with a
% PRA>0 orwith the presence of pre-transplant DSA, induction therapy
with thymoglobulin was administered.
It is important to highlight that 95% of the patients included in this
analysis had a functioning allograft at the time of the database review.
The graft function analysis by % PRA groups revealed very similar eGFR
in the 0% and 1–19% PRA groups (65 ± 20.12 ml/min vs. 64.9 ±
22.5 ml/min, respectively). These similarities seem to support the
statistical ﬁndings thatwere presented in the risk analysis, consequently
implying that the sensitization characteristics and tendency towards
immune mediated graft dysfunction are constant with a % PRA b20.
In a recent retrospective and single center study by Dunn et al., the
authors concluded that the best short and long-term immunologic
outcomes occur when donor sensitization is avoided, and that
historically accepted risk factors such as % PRA, pre-transplant and
DD grafts do not necessarily confer signiﬁcant immunologic risk and
probability of adequate outcomes. However, a probabilistic analysis
focusing on the event of transplantation with these characteristics
was not provided [19].
Table 2
Graft function analysis and acute rejection rates by % PRA groups.
% PRA group PRA 0% (n = 50) 1–19% (n = 15) 20–79% (n = 14) 80–100% (n = 4) Unknown (n = 17)
Donor gender (F/M) 15/35 6/9 8/6 2/2 11/6
Donor mean age (years) 32.2 ± 12.5 36 ± 10.8 35.5 ± 12.4 32.5 ± 15.9 39.1 ± 14.8
1-year post-KT eGFR by MDRD (ml/min) 67 ± 18.9 63.1 ± 19.4 57.7 ± 22.5 54.5 ± 17.4 55.6 ± 18.5
Latest eGFR by MDRD (ml/min) 65 ± 20.12 64.9 ± 22.5 55 ± 21.8 56 ± 17.5 50.25 ± 26.85
Latest serum creatinine (mg/dl) 1.3 ± 0.34 1.5 ± 1.03 1.5 ± 0.9 1.4 ± 0.5 2.2 ± 2.3
Acute rejection rate (%) 16% 20% 14% 25% 35%
Mean time to 1st acute rejection (days) 165 ± 169 99 ± 96 240 ± 243 35 243 ± 187
Mean time post-KT (years) 2.8 ± 1.9 2.8 ± 2 2.7 ± 1.7 1.7 ± 1 5.8 ± 1.8
157I.C. Bostock et al. / Transplant Immunology 28 (2013) 154–158The impact of an episode of acute rejection on graft function seems
undeniable [20–22]; in our series an eGFR of 43 ± 22.9 ml/min
vs. 67.7 ± 17.9 ml/min was documented in the patients with an
episode of AR vs. those patients without history of rejection.
In conclusion, this information suggests that excluding sensitized
patients from theDDwaiting list should not be favored, although a thor-
ough explanation and preparation of the patients for a longer time peri-
od on the waiting list should be emphasized. Although this study was
carried out in a limited population, when a patient with a high % PRA
overcomes the immunological barriers for transplantation and receives
a kidney, the functional graft outcomes seem to be very similar to
the patients with lesser PRA percentages in the short run. However,
long-term follow up is deserved to know the fate of graft and patient
survival in this patient population with different pre-transplant % PRA.
The tendency for the generalization of single antigen determination in
the pre-transplant screening in our setting will most likely favor the
organ assignment process and prioritize adequate outcomes. As was
reported by Fuggle et al., the tendency for the generalization of single
antigen determination in the pre-transplant screening in our setting
will most likely favor the organ assignment process and prioritize ade-
quate outcomes by increasing antibody speciﬁcity deﬁnition and the
understanding of a patient's sensitization proﬁle [23].Author contributions
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